Sanofi, GSK virus booster shot data in early 2022

Wednesday, 15. December 2021 11:24

Sanofi SA and GlaxoSmithKline (GSK) PLC announced on Wednesday they will reveal the results of clinical trials of the booster dose of their vaccine against COVID-19 in the first quarter of 2022 instead of at the end of this year as originally planned.

The companies said that their study has so far shown that "a single booster dose of their recombinant adjuvanted COVID-19 vaccine candidate delivered consistently strong immune responses."

"These preliminary data show we have a strong booster candidate, whatever primary vaccine you have received," Sanofi Executive Vice President Thomas Triomphe. "While pursuing a phase 3 trial is a challenge in a quickly shifting pandemic environment, we look forward to seeing the results to support submissions of our booster vaccine as quickly as possible."

Related Links: Sanofi S.A.GlaxoSmithKline PLC
Baha Breaking News (BBN) / JR